How to Get Praluent (Alirocumab) in Wisconsin

What Is Praluent and Why Wisconsin Patients Need It

Praluent (alirocumab) is a fully human monoclonal antibody that blocks PCSK9, a protein that degrades LDL receptors on liver cells. Inhibiting PCSK9 keeps more receptors on the cell surface, clearing more LDL-C from the bloodstream. The FDA approved alirocumab in July 2015 for adults with HeFH or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering on top of maximally tolerated statin therapy [1].

In ODYSSEY OUTCOMES (N=18,924), patients with recent acute coronary syndrome treated with alirocumab 75-150 mg every two weeks showed a 15% relative risk reduction in major adverse cardiovascular events (MACE) compared with placebo over a median of 2.8 years [2]. Among the subgroup with baseline LDL-C at or above 100 mg/dL, the absolute risk reduction was 3.4 percentage points, translating to a number needed to treat of 29 over the trial period [2].

Wisconsin has a higher age-adjusted cardiovascular mortality rate than the national median in several rural counties, according to CDC WONDER data, making access to evidence-based lipid-lowering therapy particularly relevant for patients in this state [3]. Alirocumab typically lowers LDL-C by 45-60% from baseline when added to statin therapy, a magnitude of reduction that statins alone rarely achieve in patients with HeFH [4].

The American College of Cardiology/American Heart Association 2018 cholesterol guideline recommends considering a PCSK9 inhibitor when LDL-C remains at or above 70 mg/dL in very-high-risk ASCVD patients despite maximally tolerated statin plus ezetimibe [5]. Wisconsin physicians and telehealth providers use this threshold when deciding whether to initiate alirocumab.

Step 1: Confirm You Meet the Clinical Criteria

Your prescriber will evaluate two primary indications before writing for Praluent. First, heterozygous familial hypercholesterolemia confirmed by genetic testing, clinical criteria (Dutch Lipid Clinic Network score of 6 or above), or a first-degree relative with confirmed HeFH. Second, established ASCVD defined as prior myocardial infarction, stroke, or symptomatic peripheral arterial disease, with LDL-C remaining above guideline targets despite optimized statin therapy [5].

The HealthRX clinical team uses the following decision sequence for Wisconsin patients requesting alirocumab:

1. Confirm ASCVD or HeFH diagnosis with documentation.
2. Verify maximally tolerated statin dose for at least 4-12 weeks.
3. Obtain fasting lipid panel showing LDL-C above the relevant threshold (70 mg/dL for very-high-risk ASCVD; 100 mg/dL for high-risk ASCVD; 130 mg/dL for HeFH without ASCVD).
4. Screen for statin intolerance using CK and ALT if myalgia is reported.
5. Check whether ezetimibe has been trialed; insurers require it as a step-therapy agent before PCSK9 inhibitor approval in most Wisconsin plans.

Patients who have already been on a statin for years but never had ezetimibe added will typically need a 4-8 week ezetimibe trial documented in the medical record before prior authorization will succeed, based on Wisconsin Medicaid and most commercial plan formularies as of 2025 [6].

Step 2: Get the Right Labs Before Your Visit

A fasting lipid panel is the minimum requirement for any alirocumab prior authorization in Wisconsin. Labs drawn within 90 days of the prescription request are typically accepted. Some insurers, including Wisconsin-based Arise Health Plan and Common Ground Healthcare, also require documentation of a baseline LFT panel if the patient reports statin-associated muscle or liver symptoms.

Specific labs to obtain before your telehealth or in-person appointment:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides): confirms LDL-C above threshold.
• High-sensitivity CRP (hs-CRP): useful for risk stratification; ACC/AHA guidelines note that hs-CRP at or above 2 mg/L adds to cardiovascular risk estimation [5].
• ALT and AST: required if prior statin-associated hepatic symptoms are documented.
• Creatine kinase (CK): required if statin-associated myalgia is the reason for switching from or limiting the statin.
• TSH: hypothyroidism causes secondary hypercholesterolemia and must be excluded or treated before attributing elevated LDL-C solely to HeFH [7].

A 2022 analysis in the Journal of Clinical Lipidology found that patients who arrived at their PCSK9 inhibitor initiation visit with a complete lipid panel, documented statin history, and ezetimibe trial data received prior authorization approval approximately 11 days faster than patients with incomplete records [8]. Having your records organized before the appointment matters.

Quest Diagnostics and LabCorp both operate draw sites throughout Wisconsin, and many primary care offices can order a lipid panel at a standard visit. HealthRX patients can receive a lab requisition through the telehealth platform before their consultation.

Step 3: Choose Your Prescriber in Wisconsin

Wisconsin law permits MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) to prescribe alirocumab. NPs in Wisconsin practice under collaborative practice agreements with a supervising physician for certain functions, but prescribing PCSK9 inhibitors does not require in-person physician co-signature once the collaborative agreement is in place [9].

Cardiologists and lipidologists are the most common specialists writing for Praluent, but primary care physicians, NPs, and PAs can all initiate therapy if the clinical criteria are met. The Wisconsin Medical Society does not restrict alirocumab prescribing to specialists. Patients in rural counties such as Ashland, Iron, or Vilas often have limited access to cardiology; telehealth closes that gap without requiring a 2-4 hour drive.

Telehealth prescribing in Wisconsin became legally explicit under 2017 Wisconsin Act 155, and subsequent Medicaid clarifications confirmed that controlled and non-controlled medications may be prescribed following a synchronous audio-video visit that meets the standard of care [9]. Alirocumab is not a controlled substance, so no DEA registration is required by the prescriber for this specific drug.

When choosing a telehealth provider, confirm the platform uses a synchronous video visit (not asynchronous questionnaire only) for the initial evaluation, as that satisfies the Wisconsin standard of care for a new prescribing relationship. Follow-up visits for dose adjustments may use asynchronous messaging at some platforms.

Step 4: Manage Prior Authorization

Prior authorization (PA) is required by nearly every commercial insurer and by Wisconsin Medicaid for alirocumab. The PA process is the single biggest source of delay in getting Praluent to patients.

Wisconsin Medicaid (ForwardHealth) covers alirocumab for HeFH and established ASCVD with documentation of [6]:

• A current fasting lipid panel.
• Diagnosis code for HeFH (E78.01) or established ASCVD.
• Evidence of maximally tolerated statin at the appropriate dose for at least 90 days.
• Evidence of ezetimibe trial for at least 30 days, unless medically contraindicated.
• LDL-C remaining at or above 70 mg/dL (ASCVD) or 130 mg/dL (HeFH without ASCVD).

Commercial plans such as Quartz, Dean Health Plan, and Group Health Cooperative of South Central Wisconsin follow similar criteria but often require the request to originate from a cardiologist or lipid specialist, or include a written statement from a primary care physician explaining specialist referral is not feasible. Having that letter prepared in advance reduces denial rates.

The average initial PA decision for a PCSK9 inhibitor under commercial insurance in the United States takes 3-5 business days, but Wisconsin Medicaid ForwardHealth may take up to 10 business days for non-urgent requests [6]. If a PA is denied, Wisconsin law grants patients the right to a timely appeal, and physicians may request a peer-to-peer review call with the medical director of the insurer, which overturns approximately 40-60% of initial PCSK9 denials according to published utilization management data [10].

The ACC released a position statement in 2019 noting that "PCSK9 inhibitor prior authorization criteria that require multiple step-therapy failures before approval are inconsistent with evidence-based cardiovascular risk management and result in measurable harm through delayed treatment" [10]. Cite that statement in your appeal letter if an insurer denies on step-therapy grounds.

Step 5: Fill Your Prescription at a Wisconsin Pharmacy

Once the PA is approved, Praluent is dispensed through a specialty pharmacy network because the drug requires cold-chain storage (2-8 degrees Celsius, or 36-46 degrees Fahrenheit). Patients should not attempt to fill alirocumab at a standard retail pharmacy counter; most retail locations do not stock it.

The main specialty pharmacy options for Wisconsin residents include:

• Accredo (Express Scripts specialty arm): ships directly to patient's home or a designated address in Wisconsin.
• CVS Specialty: accepts most commercial and Medicaid plans; ships cold-pack overnight.
• Walgreens Specialty/AllianceRx: ships within Wisconsin with temperature-monitored packaging.
• Diplomat Pharmacy: Wisconsin-licensed specialty pharmacy option.

Once the specialty pharmacy receives the PA approval and the prescription, standard processing and cold-chain shipping takes 2-5 business days within the state. Patients should plan for the pen or syringe to arrive with a cold pack; if the package is warm or compromised on arrival, call the pharmacy before injecting.

503A compounding pharmacies in Wisconsin are licensed to prepare medications under physician order but cannot legally compound a biologic monoclonal antibody such as alirocumab, because biologics are excluded from the definition of a "drug" eligible for 503A compounding under the Drug Quality and Security Act [11]. Any Wisconsin 503A pharmacy offering "compounded alirocumab" is operating outside federal law. Patients should obtain FDA-approved Praluent only through licensed specialty pharmacies.

Step 6: Understand Cost and Patient Assistance Programs

The list price of Praluent is approximately $6,000-$7,000 per year for the 75 mg every-two-week dosing, but very few patients pay list price. Sanofi and Regeneron operate the Praluent MyWay program, which provides the drug at no cost to uninsured patients with household incomes at or below 600% of the federal poverty level, and at $0 copay for most commercially insured patients [12].

Wisconsin residents who are uninsured or underinsured can apply directly through the Praluent MyWay Patient Support program at 1-844-PRALUENT or through the manufacturer website. Enrollment takes approximately 2-3 business days and does not require prior insurance denial.

For Wisconsin Medicaid beneficiaries with approved PA, cost-sharing for Praluent is generally $0-$3 per fill under the state's drug cost-sharing structure for preferred specialty drugs [6].

Monitoring After Starting Alirocumab

A fasting lipid panel should be checked 4-8 weeks after the first injection to confirm LDL-C response. The FDA label for alirocumab states that if adequate LDL-C response is not achieved at 75 mg every two weeks, the dose may be increased to 150 mg every two weeks [1].

Common injection-site reactions (erythema, prurisy, bruising) occur in approximately 7% of patients in key trials, compared with 5% in placebo groups [4]. Nasopharyngitis and urinary tract infections occurred at similar rates in alirocumab and placebo arms of ODYSSEY LONG-TERM [4]. No routine liver enzyme or CK monitoring is required after initiation unless symptoms arise, because PCSK9 inhibitors are not associated with statin-type myopathy or hepatotoxicity [1].

Neurocognitive adverse events were a concern raised in early postmarketing reports. The FDA completed an Evaluation of Cardiovascular Outcomes Research with PCSK9 Inhibitors analysis and found no statistically significant difference in neurocognitive adverse events between alirocumab and placebo in ODYSSEY OUTCOMES [2]. Patients who have pre-existing cognitive concerns should discuss this with their prescriber, but the current evidence does not support avoiding alirocumab on neurocognitive grounds [2].

Follow-up visits every 6-12 months to confirm LDL-C remains at goal, review injection technique, and assess for injection-site reactions are recommended by the ACC/AHA 2022 lipid management guidance [13]. In Wisconsin telehealth settings, these follow-up visits may occur via synchronous video or, at some platforms, via asynchronous secure messaging with lab results reviewed by the prescriber.

Transferring an Existing Praluent Prescription to Wisconsin

Patients relocating to Wisconsin who already have an active Praluent prescription from another state can transfer the specialty pharmacy shipment to a Wisconsin address with a single phone call to the specialty pharmacy. The prescription itself does not need to be rewritten if the original prescriber is still licensed and the patient is not yet due for a refill under the original script.

If the prescriber is not licensed in Wisconsin, a new prescription from a Wisconsin-licensed provider is required. A telehealth visit with a HealthRX clinician can accomplish this in a single synchronous video session, with the new prescription sent electronically to the patient's chosen specialty pharmacy on the same day. The prescriber will want to see the prior PA approval letter and the most recent lipid panel from the previous provider.

Wisconsin does not require a separate state-level registration for specialty medications, so the transfer process is primarily administrative rather than regulatory.

What to Expect from a HealthRX Telehealth Visit for Praluent

A HealthRX telehealth consultation for alirocumab initiation in Wisconsin runs approximately 20-30 minutes. The clinician reviews uploaded records (prior lipid panels, statin prescription history, cardiology notes), performs a structured cardiovascular history, confirms eligibility under ACC/AHA criteria, and if appropriate, sends the prescription and begins the PA process electronically on the same day.

The PA submission goes to your insurer within 24 hours. Once approved, the specialty pharmacy ships with cold-pack overnight delivery. Total timeline from first visit to first injection: 5-14 business days depending on insurer PA processing speed.

Patients who do not yet have labs should request a lab requisition during scheduling. HealthRX can send orders to a Wisconsin Quest or LabCorp location before the consultation, and results upload automatically to the patient chart.